darunavir has been researched along with Long QT Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danzi, GB; Di Tano, G; Gherbesi, E; Loffi, M; Moschini, L; Regazzoni, V | 1 |
| Aureau, I; Bernard, N; Bonnet, F; Bouchet, S; Contis, A; Hessamfar, M; Lahouati, M; Lapoirie, J; Meriglier, E; Pedeboscq, S; Rivoisy, C; Sacher, F; Sacristan, B; Vandenhende, MA | 1 |
2 other study(ies) available for darunavir and Long QT Syndrome
| Article | Year |
|---|---|
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Darunavir; Electrocardiography; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Male; Middle Aged; Ritonavir; SARS-CoV-2 | 2021 |
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Topics: Antiviral Agents; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Therapy, Combination; Electrocardiography; France; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2021 |